多西他赛联合化疗一线治疗胃癌进展期有效性与安全性研究.docVIP

多西他赛联合化疗一线治疗胃癌进展期的有效性和安全性研究 　　[摘要]目的 探讨胃癌进展期采用多西他赛联合化疗一线治疗的有效性与安全性。方法 对2015年3月～2016年3月本院收治的60例进展期胃癌患者的一般资料进行回顾性分析，按照治疗方法的不同，分为观察组与对照组，每组各30例，观察组采取多西他赛、奥沙利铂联合氟尿嘧啶方案（DOF方案），对照组采用多西他赛、顺铂联合卡培他滨方案（DCX方案）。比较两组治疗效果及不良反应发生情况。结果 两组总有效率、总控制率比较，差异无统计学意义（P0.05）；两组患者不良反应主要为血小板下降、白细胞下降、恶心呕吐、腹泻、中性粒细胞下降，且观察组不良反应发生情况优于对照组，血小板下降、中性粒细胞下降发生率比较，差异有统计学意义（χ2=4.81、14.70，P=0.028、0.000）。结论 DOF方案与DCX方案治疗胃癌进展期的近期疗效相似，但DOF方案的不良反应较DCX方案低，安全性高，值得深入研究和推广 [关键词]多西他赛；胃癌；进展期；联合化疗 [中图分类号] R735.2 [文献标识码] A [文章编号] 1674-4721（2016）10（a）-0098-03 [Abstract]Objective To explore the effective and safety of using docetaxel combined chemotherapy as first-line chemotherapy in advanced gastric cancer.Methods General data of 60 patients with advanced gastric cancer in the hospital from March 2015 to March 2016 were retrospectively analyzed.According to different treatment methods，60 patients with advanced gastric cancer were divided into observation group （DOF program：Docetaxel，Oxaliplatin and Fluorouracil treatment） and control group （DCX program：Docetaxel，Cisplatin combined with Capecitabine treatment）.The treatment effects and occurrence of adverse reactions in two groups were compared.Results Total effective rate and total control rate between two groups had no obvious difference （P0.05）；the adverse reactions in two groups were mainly of thrombocytopenia，white blood cell decline，nausea and vomiting，diarrhea and neutrophil decline，and the adverse effects in the observation group were better than those in the control group，and the difference was statistically significant （χ2=4.81、14.70，P=0.028、0.000）.Conclusion The DOF program and DCX program have similar short-term effects in treating advanced gastric cancer，while DOF program has less adverse reactions and higher safety than DCX program，which is worth to further research and extension. [Key words]Docetaxel；Gastric cancer；Progressive stage；Combined chemotherapy 胃癌是国内常见疾病类型，发病率与致死率占恶性肿瘤之首[1]。进展期胃癌又被称为中、晚期胃癌，发病率为胃癌的60%～80%[2]。化疗是临床上治疗进展期胃癌的常用方法，且化疗多采用